[Abstract] Small molecule peptide probe needle can achieve rapid metabolism of malignant tumor target molecular diagnosis
Tumors seriously endanger people's physical and mental health and life. With the advent of precision medicine, it has become important to carry out preliminary screening and molecular structure-targeted drug therapy based on molecular structure markers of malignant tumors.
Tumors seriously endanger people's physical and mental health and life. With the advent of precision medicine, it has become important to carry out preliminary screening and molecular structure-targeted drug therapy based on molecular structure markers of malignant tumors. Among them, using bioactive molecular structure as a non-specific discriminant component to carry out high-precision examination and precise positioning of malignant tumors has the development potential. Active small molecule peptide probes have the characteristics of good selectivity, low antigenicity, good compatibility, strong penetrability, and easy metabolism elimination, etc., which will show strong advantages in cancer diagnosis and treatment, and even have the development tendency to replace traditional antigens for diagnosis and treatment.
Recently, a team of researchers from the National Center for Research and Management of Nanotechnology and the Department of Chemistry at Stanford university, in collaboration with the National Center for Research and Management of Nanotechnology, used an active small molecule peptide molecular structure probe to complete the rapid metabolism of malignant tumor target molecular diagnosis. First, the authors obtained a novel target active peptide CP for tumor stem cell marker CD133 based on high-throughput screening of microarrays. The affinity dissociation constant Kd of CP and CD133 was nM heavy and close to antigen binding. Next, they used CP as the target molecular structure to decorate the bright light molecular structure of nIR-II. Compared with the common visible light and its near infrared spectrometer in the first area of the bright light imaging, the second area of the near infrared spectrometer (the inspection dialog box is 1000-1700nm), because of the longer wavelength of light, the light transmission of biological tissues and the self-bright light efficiency are significantly reduced. The detection depth is deeper and the time screen resolution is higher.
Scholars prepared a new type of water-soluble NIR-II aquamarine small molecule water IRT, and carried out tail vein infusion and the manifestation of living malignant tumors according to the coupling reaction of Click response and CP active small molecule peptide. Compared with the molecular structure without target, CP-IRT can achieve the maximum data signal within 2 hours. Because most of the glow-light nano-technology probes in the body metabolism is very slow, long-term residual in the liver, liver and other human organs, blocking the clinical medical conversion. CP-IRT, decorated with small molecular peptides, can be rapidly metabolized by kidney function and bladder light. In contrast, antigen-decorated IRT aggregates in the liver due to significantly enlarged specifications, despite the same target efficacy. In 6 hours, ninety percent of the CP-IRT can be excreted out of the body, and they used this probe for the first time to perform NIR-II light imaging of the urethra.
The results were recently published in AdvancedMaterials.The first authors are Weizhi Wang, an associate researcher at the National Center for Nanotechnology Research and Management, and Zhuoran Ma, a doctoral candidate at Stanford University, Corresponding authors are Dai Hongjie, an expert professor at Stanford University, Liang Yongye, an expert professor at South China University of Science and Technology, and Hu Zhiyuan, a researcher at the National Nanotechnology Research And Manageme...
(All Rights Reserved)